10 Best Mid Cap Biotech Stocks to Buy

6. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Market Cap: $7.14 billion

Number of Hedge Fund Holders: 50

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities to treat rare diseases. The company has several approved products to treat Duchenne muscular dystrophy and is developing potential therapeutical candidates for more disorders, including neuromuscular and central nervous system-related disorders. Its pipeline comprises more than 40 programs at various discovery, pre-clinical, and clinical development stages.

While there is some uncertainty going on regarding the company’s future due to its product Elevidys’ alleged involvement in a fatal acute liver case, Mizuho views the selloff in shares of the company due to these concerns as a “compelling buying opportunity.” It is likely for physician and patient behavior to remain unchanged as Elevidys helps fill a dire need in Duchenne muscular dystrophy. The analyst told investors in a research note on March 19 that Sarepta Therapeutics, Inc.’s (NASDAQ:SRPT) current stock price primarily encompasses the value for its exon-skipping business and limb-girdle, which together add up to $70 per share, instead of Elevidys. The firm sees a “significant” increase in SRPT’s interest at the current stock price.

In a report released on March 21, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics, Inc. (NASDAQ:SRPT), with a price target of $123.00. It is the sixth best mid cap biotech stock to buy now on our list.